National Institute for Health and Care Excellence10s
Accident and injury prevention
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
National Institute for Health and Care Excellence5h
In consultation: Guidance and quality standards
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease Interventional procedure consultation Interventional procedures guidance 12 December 2024 Zilucoplan for treating ...
National Institute for Health and Care Excellence5h
New joint guideline recommends prescribing combination treatments for people with newly diagnosed asthma
It recommends healthcare practitioners should offer a low-dose combination of inhaled corticosteroids (ICS) and formoterol to be taken as needed for everyone aged 12 and over with newly diagnosed ...
National Institute for Health and Care Excellence1d
Non-executive director recruitment
Join the NICE Board as a non-executive director and help shape the future of health and social care improvement. These cookies remember information that changes the way our website behaves or looks, ...
National Institute for Health and Care Excellence5d
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy TS ID 12118
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy TS ID 12115
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence5d
Noninvasive Vagus Nerve Stimulation For reactive airway disease
For further information on how we select topics for development, please see our page about topic selection ...
National Institute for Health and Care Excellence6d
NICE responds to failure of talks to reach price agreement on Enhertu
We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...